Comprehensive Genomic Analysis of the Prognostic and Immunological Characteristics of Tertiary Lymphoid structures and CD8+ T-cells in Pancreatic Ductal Adenocarcinoma
Hao Hu,Yang Xu,Xiangnan Ai,Tengfei Wang,Huixing Li,Jin Changguo,Caiguo Ouyang,Zhenyu Wu
DOI: https://doi.org/10.21203/rs.3.rs-2860058/v1
2023-01-01
Abstract:Background Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is associated with poor prognosis. Previous publications have indicated tertiary lymphoid structure (TLSs) and CD8 + T-cells as prognostic indicators for PDAC, and a positive correlation between CD8 + T-cell infiltration and TLSs was also observed in PDAC. However, different states of TLSs infiltration occurs, and not all stages of TLSs maturation are correlated with a high abundance of CD8 + T-cells in the tumor microenvironment (TME), also CD8 + T-cell infiltration could be influenced by other factors, thus an integrative characterization of the TLSs and CD8 + T-cells is urgently needed. Herein, we aimed to establish a novel scoring system for evaluating the risk for PDAC based on TLSs- and CD8 + T-cells-related genes. Methods In this study, we analyzed single-cell sequence (scRNA-seq) data from PDAC patients in GSA: CRA001160 cohort, which indicated the positive relationship between TLSs presence and CD8 + T-cell infiltration. TCGA-PAAD was used as the training cohort. ICGC-CA, E-MTAB-6134, and the joint cohort of GSE71729 and GSE85916 were used for validation. Using bioinformatics and machine algorithms, we established and validated a scoring method (T-C score) based on survival related genes highly expressed in TLSs and CD8 + T-cells in PDAC, which was then used to stratify patients into the low- and high- T-C score groups. Following that, we analyzed the differences in survival, pathway enrichment, mutation status, immune cell infiltration, expression of immune checkpoint associated genes, tumor stemness, and response to anti-tumor therapy between the two groups. Results The overall survival differed significantly between the low- and high- T-C score groups throughout the training and validation cohort. Good accuracy of the T-C score in predicting 1-, 2-, 3-, 4-, and 5-year survival was further confirmed in the training and validation cohort, respectively. Furthermore, the low T-C score group was correlated with lower tumor mutation burden (TMB), and lower levels of tumor stemness, compared to the high T-C score group, Besides, analysis using the TIDE web tool has verified that patients with lower T-C score exhibited advantages in immunotherapeutic responses. Patients with lower T-C scores might be more sensitive to the chemotherapeutic regimen and multi-kinase inhibitors. Collectively, the T-C score based on the TLSs- and CD8 + T-cells-related gene signature could serve as an effective model for predicting the survival and therapeutic responses of PDAC patients.